Equities

GMVDF

KYG394621414

Market Closed - OTC Markets Other stock markets 10:40:56 2024-05-31 am EDT			5-day change	1st Jan Change
0.014 ^USD	+7.69%		+18.64%	-35.19%

2023	G Medical Innovations Holdings Ltd announced that it has received $0.5 million in funding	CI
2023	G Medical Innovations Holdings Ltd announced that it expects to receive $0.5 million in funding	CI

G Medical Innovations Holdings Ltd Reports Earnings Results for the Half Year Ended June 30, 2022

November 18, 2022 at 05:26 pm EST

G Medical Innovations Holdings Ltd reported earnings results for the half year ended June 30, 2022. For the half year, the company reported revenue was USD 2.22 million compared to USD 2.93 million a year ago. Net loss was USD 13.02 million compared to USD 4.69 million a year ago.

Basic loss per share from continuing operations was USD 25.2 compared to USD 17.85 a year ago.

Latest news about G MEDPAR

G Medical Innovations Holdings Ltd announced that it has received $0.5 million in funding	23-10-24	CI
G Medical Innovations Holdings Ltd announced that it expects to receive $0.5 million in funding	23-09-28	CI
G Medical Innovations Holdings Ltd Announces CFO Changes	23-09-22	CI
G Medical Innovations Holdings Ltd(OTCPK:GMVD.F) dropped from NASDAQ Composite Index	23-08-23	CI
Certain Options of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023.	23-06-29	CI
Certain Covertible Debentures of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023.	23-06-29	CI
Certain Warrants of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023.	23-06-29	CI
Certain Ordinary Shares of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023.	23-06-29	CI
Certain Rights of G Medical Innovations Holdings Ltd are subject to a Lock-Up Agreement Ending on 30-JUN-2023.	23-06-29	CI
ThinkEquity Initiates G Medical Innovations at Buy Rating With $4 Price Target	23-06-20	MT
G Medical Innovations Holdings Ltd Announces Executive Changes	23-06-01	CI
Tranche Update on G Medical Innovations Holdings Ltd's Equity Buyback Plan announced on May 20, 2022.	23-05-16	CI
Tranche Update on G Medical Innovations Holdings Ltd's Equity Buyback Plan announced on May 20, 2022.	23-05-16	CI
G Medical Innovations Holdings Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-16	CI
G Medical Innovations Says Nasdaq's Hearings Panel Grants Request for Continued Listing	23-05-15	MT
G Medical Innovations Closes $9.6 Million Securities Offering	23-04-04	MT
Sector Update: Health Care Stocks Advancing Late Friday	23-03-31	MT
Sector Update: Health Care Stocks Advancing Friday Afternoon	23-03-31	MT
Top Midday Decliners	23-03-31	MT
G Medical Innovations Prices $9.6 Million Securities Offering; Shares Fall	23-03-31	MT
Wall Street Set to Open Modestly Higher as Inflation Gauge Meets Expectations	23-03-31	MT
Top Premarket Gainers	23-03-31	MT
G Medical Innovations Holdings Ltd. and MiCare Path Announce Joint Collaboration to Provide Innovative Patient Monitoring Solutions Globally	23-03-27	CI
G Medical Innovations Holdings Ltd Announces Resignation of Dr. Brendan de Kauwe as a Member of Board of Directors	23-02-28	CI
Sector Update: Health Care Stocks' Losses Gain Speed Near Monday Close	23-01-30	MT

Chart G MEDPAR

Duration

Period

More charts

Company Profile

G Medical Innovations Holdings Ltd. is a mobile health (mHealth) and e-health company. The Company is focused on the development of mHealth and telemedicine solutions and monitoring service platforms. It develops and markets clinical and consumer medical-grade health monitoring solutions and offers end-to-end support for e-health projects. Its product lines consist of its Prizma medical device, a clinical grade device that can transform any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography data continuously, including its QT Prolongation Syndrome Detection Capabilities Patch. Its monitoring services include the provision of independent diagnostic testing facilities and private monitoring services. It also develops wireless vital signs monitoring systems.

Sector

More about the company